Omnicell (OMCL) Price Target Increased to $70.00 by Analysts at Cantor Fitzgerald

Omnicell (NASDAQ:OMCL) had its target price upped by Cantor Fitzgerald from $63.00 to $70.00 in a report released on Friday morning, The Fly reports. Cantor Fitzgerald currently has an overweight rating on the stock.

Other research analysts also recently issued research reports about the company. TheStreet raised Omnicell from a c+ rating to a b rating in a research note on Friday, July 27th. Benchmark raised their price objective on Omnicell from $66.00 to $79.00 and gave the stock a buy rating in a research note on Friday, October 5th. BidaskClub downgraded Omnicell from a strong-buy rating to a buy rating in a research note on Thursday, October 4th. Craig Hallum raised Omnicell from a hold rating to a buy rating and set a $33.00 price objective on the stock in a research note on Friday, July 27th. Finally, Zacks Investment Research raised Omnicell from a sell rating to a hold rating in a research note on Monday, August 13th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $71.33.

Shares of NASDAQ OMCL traded up $2.99 during trading on Friday, hitting $64.50. The company had a trading volume of 1,023,660 shares, compared to its average volume of 329,287. The company has a quick ratio of 1.27, a current ratio of 1.78 and a debt-to-equity ratio of 0.31. Omnicell has a 12 month low of $39.75 and a 12 month high of $73.00. The company has a market capitalization of $2.42 billion, a P/E ratio of 358.33, a price-to-earnings-growth ratio of 3.04 and a beta of 0.98.



Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, July 26th. The company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.39 by $0.07. Omnicell had a return on equity of 8.12% and a net margin of 6.11%. The firm had revenue of $188.70 million for the quarter, compared to the consensus estimate of $188.80 million. During the same quarter last year, the company earned $0.31 earnings per share. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. Research analysts anticipate that Omnicell will post 1.35 EPS for the current year.

In related news, EVP Jorge R. Taborga sold 17,644 shares of Omnicell stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $58.77, for a total transaction of $1,036,937.88. Following the sale, the executive vice president now owns 44,973 shares of the company’s stock, valued at approximately $2,643,063.21. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James T. Judson sold 5,000 shares of Omnicell stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $58.76, for a total value of $293,800.00. Following the sale, the director now directly owns 39,952 shares in the company, valued at approximately $2,347,579.52. The disclosure for this sale can be found here. Insiders have sold a total of 44,478 shares of company stock worth $2,812,339 in the last three months. 3.71% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. EULAV Asset Management purchased a new position in Omnicell during the 3rd quarter valued at approximately $1,086,000. Russell Investments Group Ltd. grew its holdings in Omnicell by 5.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 430,736 shares of the company’s stock valued at $30,970,000 after buying an additional 22,182 shares in the last quarter. Conestoga Capital Advisors LLC grew its holdings in Omnicell by 12.4% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 2,060,908 shares of the company’s stock valued at $148,179,000 after buying an additional 227,685 shares in the last quarter. Creative Planning purchased a new position in Omnicell during the 3rd quarter valued at approximately $418,000. Finally, First Trust Advisors LP grew its holdings in Omnicell by 1,248.1% during the 3rd quarter. First Trust Advisors LP now owns 68,552 shares of the company’s stock valued at $4,929,000 after buying an additional 63,467 shares in the last quarter. 98.80% of the stock is currently owned by institutional investors.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.

Recommended Story: Diversification

The Fly

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply